Clinical trial
A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa
NCT04917874 · Krystal Biotech, Inc., Industry · Completed
Key facts
| NCT number | NCT04917874 |
|---|---|
| Title | A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa |
| Official title | Open Label Treatment of Beremagene Geperpavec (B-VEC) |
| Lead sponsor | Krystal Biotech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa |
| Intervention type | Biological |
| Interventions | Open Label Topical Beremagene Geperpavec (B-VEC) |
| Enrollment | 47 |
| Start date | May 25, 2021 |
| Primary completion | Jul 31, 2023 |
| Completion | Jul 31, 2023 |
| First posted | Jun 8, 2021 |
| Last update posted | Apr 9, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: